The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.
A 22-year-old used oral finasteride from Costco and topical Kirkland minoxidil for 4-5 months to treat hair loss, resulting in significant hair regrowth and restored confidence. The "big 3" refers to minoxidil, finasteride, and microneedling as hair loss treatments.
The conversation discusses biannual SCUBE3 injections and microneedling as treatments for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.
Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.
A user shared their 3-month hair regrowth progress using finasteride, minoxidil, Redensyl, and a derma roller, along with vitamin and biotin supplements. They have seen significant improvement and regained confidence, despite initially losing hair due to seborrheic dermatitis and male pattern baldness.
A user improved their hair loss from NW3+ to NW1.5 over three years using a regimen of dutasteride, finasteride, Nizoral, biotin, and collagen. They experienced some side effects and adjusted dosages over time, and noted additional benefits like better skin and muscle gain.
A user ordered Alpha Plus from Anagenica, expecting it to contain specific percentages of Fin, Estradiol, Minoxidil, and CB0301. However, the received product's label showed different percentages, including a surprising 25% CB, leading the user to question its safety and accuracy.
Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.
Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.
GHK-Cu and Acetyl Tetrapeptide-3 are ineffective for hair regrowth according to user experiences. Effective treatments mentioned are finasteride, dutasteride, and minoxidil.
SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.
The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.
The conversation is about a user's 3-month hair regrowth progress using finasteride, minoxidil, and a 0.5mm dermaroller, with recent addition of caffeine shampoo. Users are responding positively and inquiring about application methods.
Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.
PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
A user's progress after 15 months of using the "Big 3" treatments for hair loss (finasteride, minoxidil and micro needling) as well as Nizerol 2%. The post encourages others to seek out available information on hair loss treatment and reassures them that if it doesn't work, it is only hair.
The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.
Breezula shows promise in stabilizing hair loss and potentially promoting regrowth at the one-year mark, offering hope for those who can't tolerate 5AR inhibitors. Its local targeting of androgen receptors could be a significant advancement if it avoids systemic side effects.
The conversation discusses alternative and unorthodox hair loss treatments, including RU58841, nandrolone, and dianabol, as well as theoretical approaches involving high doses of estrogen and selective estrogen receptor modulators. These methods are considered extreme and potentially harmful but are explored for those unable to tolerate traditional 5-alpha reductase inhibitors.
The person is using 1mg of finasteride daily, 2mg of minoxidil, and weekly dermarolling with a 1mm needle. They sometimes use topical minoxidil as well.
RU58841 helped regrow hairline without side effects for a bodybuilder using PEDs. The treatment included RU58841, finasteride, minoxidil, GKH-Cu, microneedling, and HGH.
The conversation is about a person rapidly losing hair and seeking information on the availability of a new treatment called scube3, as they have experienced side effects from current treatments like Minoxidil and finasteride. They are hoping scube3 will be approved soon as they believe it's their only remaining option.
GeneTherica is discussed as a source for RU58841, with ordering possible via WhatsApp. The conversation focuses on the legitimacy of this supplier for hair loss treatment.